Qiagen N.v. · NYSE:QGEN
Qiagen — Shareholder Meeting (June 2025)
57 slides from Qiagen's shareholder meeting presentation, Jun 26, 2025
Slide 1: Annual General Meeting
2025 Annual General Meeting Venlo, the Netherlands June 26, 2025
Slide 2: Opening
1 Opening June 26, 2025 2
Slide 3: Managing Board Report for the year ended December 31, 2024
2 Managing Board Report for the year ended December 31, 2024 (“Calendar year 2024”) June 26, 2025 3
Slide 4: Managing Board Report: Strategy Update
Managing Board Report Thierry Bernard Chief Executive Officer Strategy Update June 26, 2025 Annual General Meeting 2025 4
Slide 5: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amend
Slide 6: The value of biology has never been stronger
The value of biology has never been stronger Crucial to Improving Direct impact advancing healthcare on your science for all lives June 26, 2025 Annual General Meeting 2025 6
Slide 7: QIAGEN at a glance
QIAGEN at a glance Our products support scientists and clinicians to advance science and improve healthcare. A global company with scale ~52% Americas $1.98 bn Sales 2024 Sales 2024 ~33% EMEA ~15% Asia-Pacific / Japan Highly recurring revenues Balanced customer markets ~5,700 employees known as QIAG
Slide 8: QIAGEN more focused and stronger than ever
QIAGEN more focused and stronger than ever Growth and value ~4-6% CAGR ~$13-14 bn ~$11 bn addressable Life Molecular addressable market QIAGEN market (2028) Sciences Diagnostics customers (2024) ~50% ~50% QIAGEN Sample technologies Balanced global presence product 2024 net sales (%) groups 52 33 15
Slide 9: Leading from the first step in lab workflows
Leading from the first step in lab workflows Samples Sample preparation Detection Insights PCR QIAcuity dPCR #2 Any Genomics / NGS Sample #1 biological technologies QIAGEN Digital Insights #1 sample Diagnostic solutions QuantiFERON #1 QIAstat-Dx #3 Life Sciences Customers Molecular Diagnostics Custo
Slide 10: Strategy: Committed to solid profitable growth
Strategy: Committed to solid profitable growth Our 2028 targets Sharpen focus on growth pillars to At least $2 bn sustain profitable growth net sales CER from pillars in 2028 ~7% At least 250 bps Net sales CER CAGR Drive efficiency and digitization to fuel (2024-28) growth investments and profitabil
Slide 11: Focusing on attractive opportunities
Focusing on attractive opportunities Product PCR / Nucleic acid Sample technologies Diagnostic solutions NGS / Genomics groups amplification 2024 sales $642 mn $749 mn $300 mn $234 mn Accelerate investments for growth Build on proven leadership QIAcuity #2 QIAstat-Dx #3 QIAGEN #1 Sample #1 QuantiFER
Slide 12: Sample technologies: On the offense expanding our portfolio
Sample technologies: On the offense expanding our portfolio ≥$750 mn Sample technologies QIAmini QIAsymphony QIAsprint Connect Connect net sales CER target (2028) Launch 2026 Launch 2025 Launch 2026 Low-throughput Mid-throughput High-throughput Addition to QIAcube / EZ Flagship system upgrade, Marke
Slide 13: QuantiFERON: Driving TB test conversion with top automation
QuantiFERON: Driving TB test conversion with top automation ≥$600 mn QuantiFERON Leading automation advantage net sales CER target (2028) Automated Automated Increase liquid handling assay and result Partnership with customer base Diasorin to expand into Lyme disease (EU and U.S.) Large potential in
Slide 14: QIAstat-Dx: Expanding global presence with differentiated menu
QIAstat-Dx: Expanding global presence with differentiated menu ≥$200 mn QIAstat-Dx net sales CER target (2028) Grow installed Small hospitals Medium hospitals Large hospital networks customer Public health labs Regional reference labs National reference labs base Submitted to FDA Low-throughput High
Slide 15: QIAcuity: Significant investments into digital PCR leadership
QIAcuity: Significant investments into digital PCR leadership ≥$250 mn QIAcuity net sales CER target (2028) Accelerate Target Extend commercialization new applications into clinical use >3x increase Add >100 assays QIAcuity-Dx of sales specialists for market menu expansion for CGT and enabling MRD a
Slide 16: QDI: Investing to extend bioinformatics leadership
QDI: Investing to extend bioinformatics leadership ≥$200 mn QDI net sales CER target (2028) Extend leadership in curated Deepen global Invest in new AI and other knowledge commercial reach technologies Expand QIAGEN knowledge base into Adopt SaaS go-to-market Continue advancing software spatial, pro
Slide 17: Initiatives to fuel growth investments and achieve ≥31% margin in 2028
Initiatives to fuel growth investments and achieve ≥31% adjusted operating income margin in 2028 Operational excellence Digitization Positioning QIAGEN for stronger profitable growth Accelerating growth and efficiency across QIAGEN Organizational design Portfolio streamlining >6 million ~30 website
Slide 18: Embracing ESG for all stakeholders
Embracing ESG for all stakeholders Net zero Top ESG ratings Environmental responsibility carbon emission target (2050) Investing in people 37% female leadership (2024) Serving society >50 public health partnerships (2024) Business with integrity ~8,000 compliance trainings completed (2024) June 26,
Slide 19: 2024: Executing in a challenging environment
2024: Executing in a challenging environment net sales $1.98 bn in 2024 Sales achieved in 2024 adj. diluted QIAcuity digital PCR $80 mn $2.18 EPS in 2024 Launch of QIAcuityDx digital PCR for clinical use >100 new digital PCR assays for researchers Sales achieved in 2024 QIAstat-Dx $109 mn Sample tec
Slide 20: Q1 2025: Solid results exceeding outlook
Q1 2025: Solid results exceeding outlook Growth Solid start to 2025 with broad-based growth across the portfolio $483 mn ($491 mn CER) • Net sales +7% CER to $483 mn above outlook of ~+3% Net sales • QuantiFERON +16% CER, QIAstat-Dx +37% CER; QIAcuity and QDI delivered +7% CER high-single-digit grow
Slide 21: Proposing dividend payment and $500 mn repurchase authorization
Proposing dividend payment and $500 mn repurchase authorization Profitable targeted investments Annual dividend NEW Organic initiation investments into growth pillars and digitization to fuel profitable business expansion Seeking shareholder approval for dividend at this AGM Focused Value-creating t
Slide 22: Summary: Delivering sustainable growth in 2024
Summary: Delivering sustainable growth in 2024 Accelerating profitable sales growth with focus Leveraging continuum of research to clinical testing Expanding digitization to drive growth and efficiency Maintaining our disciplined capital allocation policy June 26, 2025 Annual General Meeting 2025 22
Slide 23: Managing Board Report: Finance
Managing Board Report Roland Sackers Chief Financial Officer Finance June 26, 2025 Annual General Meeting 2025 23
Slide 24: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amend
Slide 25: FY 2024: Exceeded outlook for net sales and adjusted EPS
FY 2024: Exceeded outlook for net sales and adjusted EPS Growth Solid sales growth exceeding outlook $1.978 bn • $1.991 bn CER above outlook of at least $1.985 bn CER 2024 ($1.991 bn CER) Net sales • Diagnostic solutions (+8% CER), Sample technologies (-3% CER) +1% CER and PCR / Nucleic acid amplifi
Slide 26: 2024: Financial review (U.S. GAAP)
2024: Financial review (U.S. GAAP) In $ millions (Except EPS and diluted shares) 2024 2023 Change Net sales 1,978 1,965 1% Net sales - CER 1,991 1% Operating income 98 410 -76% Adjusted operating income 567 529 7% Net income 84 341 -76% Adjusted net income 491 477 3% Diluted EPS $0.37 $1.48 -75% Adj
Slide 27: FY 2024: Sales performance by product group
FY 2024: Sales performance by product group Sales comparison by product group Sales performance by product group (In $ millions at actual rates) FY 2024 (In $ millions at actual rates / change in actual, CER rates) +2% core Sales % change % CER CER(1) 1,965 1,978 Sample technologies 642 -3% -3% Samp
Slide 28: 2024: Reconciliation to adjusted results (U.S. GAAP)
2024: Reconciliation to adjusted results (U.S. GAAP) (In $ millions, except EPS) Net Gross Operating Pretax Income Tax Net Diluted sales profit income income tax rate income EPS (1) Full-year 2024 Reported results 1,978.2 967.3 97.7 121.1 (37.5) 31% 83.6 0.37 Adjustments Business integration, acquis
Slide 29: 2024: Review of U.S. GAAP and IFRS results
2024: Review of U.S. GAAP and IFRS results Consolidated Income Statements for the year ended December 31, 2024 In $ millions U.S. GAAP IFRS Difference (Except per share data) 2024 2024 (U.S. GAAP vs. IFRS) Net sales 1,978.2 1,978.2 — Gross profit 967.3 961.8 5.5 Income from operations 97.7 117.3 (19
Slide 30: Healthy cash flow trends support disciplined capital allocation
Healthy cash flow trends support disciplined capital allocation Healthy cash flow strengthens balance sheet Disciplined capital allocation strategy (in $ millions) 1.5x +47% Investing in growth 715 Allocating ~9-10% of sales into R&D 674 639 0.9x 458 459 0.5x 0.6x Value-creating M&A Enhance portfoli
Slide 31: Strong balance sheet provides opportunities to create value
Strong balance sheet provides opportunities to create value Net debt as of December 31, 2024 Maturities of debt instruments(1) (in $ millions) (in $ millions) Convertible Bonds Schuldschein 1,392 1,153 615 Convertible Cash and Bonds short-term 115 500 2027 investments 2031 Likely repayment in 2025(2
Slide 32: QIAGENers are the source of our success
QIAGENers are the source of our success Employees as of December 31, 2024 Employees by region 2024 2023 Americas 1,252 1,329 Europe, Middle East & Africa 3,352 3,453 Asia Pacific, Japan and Rest of World 1,161 1,185 Total 5,765 5,967 Employees by function 2024 2023 Production 28% 28% Research & Deve
Slide 33: Investor Relations in 2024
Investor Relations in 2024 Highlights ~350 >80 >150 participants(1) at live participants of investor 2024 Capital the first QIAGEN meetings Markets Day Deep Dive in 2024 Development of sell-side analyst ratings per year 17 23 25 24 Buy 11 10 16 Hold 8 Listings Sell 12 13 9 8 1 1 2021 2022 2023 2024
Slide 34: Share price performance: January 2024 - June 2025
Share price performance: January 2024 - June 2025 Share Price Performance Since Jan-2024 140% Performance % Jan-24 1Y YTD 3M 1M QIAGEN (USD) 1.5% 8.5% 2.1% 18.8% 9.5% 130% QIAGEN (EUR) (0.2)% 4.4% (5.8)% 11.6% 6.3% Diversified¹ (22.9)% (21.5)% (21.7)% (11.6)% (0.7)% Diagnostics² (12.7)% 2.1% (9.2)%
Slide 35: EV/EBITDA trends: January - June 2025
EV/EBITDA trends: January - June 2025 2025E EV/EBITDA By decreasing order of multiple performance 29x 01-Jan Current Delta Average 14.4 x` 14.3 x (0.1)x 22.4 x 21.1 x (1.3)x 25x 18.2 x 15.7 x (2.5)x 22.1 x 19.6 x (2.5)x 21.1 x 19.9 x 17.4 x (2.5)x 21x 20.3 x 23.6 x 20.3 x (3.3)x 19.6 x 18.1 x 15.2 x
Slide 36: Summary: Solid foundation for solid profitable growth
Summary: Solid foundation for solid profitable growth Pillars lead improved sales results Enhanced margin through disciplined execution Strong level of free cash flow generation Capital allocation to increase returns and improve portfolio June 26, 2025 Annual General Meeting 2025 36
Slide 37: Supervisory Board Report on the Company's Annual Accounts
3 Supervisory Board Report on the Company‘s Annual Accounts (the “Calendar Year 2024”) for Calendar Year 2024 June 26, 2025 37
Slide 38: Adoption of the Annual Accounts for Calendar Year 2024
4 Adoption of the Annual Accounts for Calendar Year 2024 (voting item) June 26, 2025 38
Slide 39: Advisory Vote on the Remuneration Report 2024
5 Advisory Vote on the Remuneration Report 2024 (advisory voting item) June 26, 2025 39
Slide 40: Dividend policy
6 Dividend policy June 26, 2025 40
Slide 41: Adoption of the dividend for 2025
7 Adoption of the dividend for 2025 (voting item) June 26, 2025 41
Slide 42: Discharge from liability of the Managing Directors
8 Discharge from liability of the Managing Directors for the performance of their duties during Calendar Year 2024 (voting item) June 26, 2025 42
Slide 43: Discharge from liability of the Supervisory Directors
9 Discharge from liability of the Supervisory Directors for the performance of their duties during Calendar Year 2024 (voting item) June 26, 2025 43
Slide 44: Reappointment of the following eight Supervisory Directors
10 Reappointment of the following eight Supervisory Directors of the Company for a term running up to and including the date of the Annual General Meeting in 2026 (voting items): a. Dr. Metin Colpan b. Dr. Toralf Haag c. Prof. Dr. Ross L. Levine d. Dr. Eva Pisa e. Mr. Stephen H. Rusckowski f. Ms. El
Slide 45: Transition in Supervisory Board leadership and composition
Transition in Supervisory Board leadership and composition Stephen H. Rusckowski QIAGEN Supervisory Board members – To be elected Chairman of Supervisory Board(1) Returning to eight members as planned in 2024 • Joined Supervisory Board in 2023 • Currently Chair of Nomination & Governance Committee a
Slide 46: Reappointment of the following two Managing Directors
11 Reappointment of the following two Managing Directors of the Company for a term running up to and including the date of the Annual General Meeting in 2026 (voting items): a. Mr. Thierry Bernard b. Mr. Roland Sackers June 26, 2025 46
Slide 47: Adoption of the Remuneration Policy with respect to the Managing Board
12 Adoption of the Remuneration Policy with respect to the Managing Board (voting item) June 26, 2025 47
Slide 48: Authorization of the Supervisory Board to issue shares and rights
13a Authorization of the Supervisory Board, until December 26, 2026, to issue a number of ordinary shares and financing preference shares and grant rights to subscribe for such shares, the aggregate par value of which shall be equal to the aggregate par value of fifty percent (50%) of the shares iss
Slide 49: Authorization to restrict or exclude pre-emptive rights
13b Authorization of the Managing Board, until December 26, 2026, to restrict or exclude the pre-emptive rights with respect to issuing ordinary shares or granting subscription rights, the aggregate par value of such shares or subscription rights shall be up to a maximum of ten percent (10%) of the
Slide 50: Authorization to acquire shares in the Company's own share capital
14 Authorization of the Managing Board, until December 26, 2026, to acquire shares in the Company’s own share capital (voting item) June 26, 2025 50
Slide 51: Proposal to amend the Articles of Association (Part I)
15a Discretionary rights for the Managing Board to implement a capital repayment by means of synthetic share repurchase (voting item): Proposal to amend the Company’s Articles of Association in accordance with the draft deed of amendment of the Company’s Articles of Association (Part I) to, amongst
Slide 52: Proposal to amend the Articles of Association (Part II)
15b Discretionary rights for the Managing Board to implement a capital repayment by means of synthetic share repurchase (voting item): Proposal to amend the Company’s Articles of Association in accordance with the draft deed of amendment of the Company’s Articles of Association (Part II) to, amongst
Slide 53: Proposal to amend the Articles of Association (Part III)
15c Discretionary rights for the Managing Board to implement a capital repayment by means of synthetic share repurchase (voting item): Proposal to amend the Company’s Articles of Association in accordance with the draft deed of amendment of the Company’s Articles of Association (Part III) to decreas
Slide 54: Proposal to amend the Articles of Association (Part I, II and III)
15d Discretionary rights for the Managing Board to implement a capital repayment by means of synthetic share repurchase (voting item): Proposal to authorize each member of the Managing Board of the Company and each lawyer, (candidate) civil law notary and paralegal working at De Brauw Blackstone Wes
Slide 55: Cancellation of fractional ordinary shares held by the Company
16 Cancellation of fractional ordinary shares held by the Company (voting item) June 26, 2025 55
Slide 56: Questions
17 Questions June 26, 2025 56
Slide 57: Closing
18 Closing June 26, 2025 57